L1CAM and neoplasm: During this time, a reduced tumour burden with a significant decrease in average RTV on day 13 was observable for mice treated with anti-L1CAM combination therapy compared to all other treatment groups (vs. 177Lu-DOTA-chCE7: p < 0.05; vs. PTX: p < 0.05; vs. 177Lu-DOTA-control IgG + PTX: p < 0.05).